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ABSTRACT
Background: Immediate-type wheat allergy caused by a specific hydrolyzed wheat protein (HWP-IWA), Glu-
pearl 19S (GP19S), typically develops food-dependent exercise-induced anaphylaxis (FDEIA), but is different
from conventional FDEIA, or simple wheat allergy in many aspects. The skin prick test (SPT) is considered to
be the most effective method for diagnosis of HWP-IWA. As SPT is a relatively qualitative method, we devel-
oped quantitative and high-throughput test method for HWP-IWA.
Methods: An enzyme-linked immunosorbent assay (ELISA)-based GP19S-specific IgE assay was tested us-
ing sera from 14 HWP-IWA and five conventional wheat-dependent exercise-induced anaphylaxis (CO-
WDEIA) patients, as well as five healthy subjects. Then a validation study at five different institutions was car-
ried out using sera from 10 HWP-IWA and five CO-WDEIA patients, as well as five healthy subjects different
from the previous studies.
Results: The mean unit values converted from measured absorbance of ELISA were 68.3, 1.3 and 1.1 re-
spectively. Furthermore, the validation study revealed reproducible results across all five institutions, with the
standard deviation (SD) being 0.3-0.4 for the healthy group, 0.2-0.6 for the CO-WDEIA group, and 3.8-9.6 for
HWP-IWA group except for one case. One case of HWP-IWA was excluded from analysis due to the high SD of
53.3 units, indicating that samples with a unit value > 100.0 will affect inter-laboratory reproducibility.
Conclusions: Our findings suggest that the ELISA-based GP19S-specific IgE assay can be used to test
HWP-IWA using venous blood samples, except for those with a unit value > 100.0.
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INTRODUCTION
Many cases of Immediate-type allergy after wheat in-
take have been observed in Japanese consumers us-
ing cosmetics that contain hydrolyzed wheat protein
(HWP), HWP-IWA, who had used “Cha no Shizuku”
soap (sold by Yuuka, Fukuoka, Japan) that contained
Glupearl 19S (GP19S), a substance manufactured by
Katayama Chemical Industries, Osaka, Japan. HWP-
IWA patients, but not conventional wheat allergy pa-
tients, react to GP19S. Therefore, GP19S hypersensi-
tivity is essential for diagnosis of HWP-IWA.1,2
HWP is a cosmetic ingredient specified in the Japa-
nese Standards of Quasi-drug Ingredients, and which
is a collective term for water-soluble materials that
are produced by hydrolyzing wheat glutens with acid,
alkali, enzymes or other substances. Cases of HWP
allergy have been reported in Western nations; nota-
bly, cases are fewer and less severe than those in Ja-
pan.3-6 In order to address the problem of HWP al-
lergy, the “Special Committee for the Safety of Pro-
tein Hydrolysates in Cosmetics” was organized by the
Japanese Society of Allergology to study the epidemi-
ology, pathogenesis, and establish diagnostic criteria,
among other activities.
HWP-IWA is different from conventional wheat al-
lergy. In contrast to the onset of conventional wheat
allergy in children, HWP-related allergy arise in
adults with a history of cosmetic use.7 Although both
conventional and HWP-related wheat allergy in adults
can cause wheat-dependent exercise-induced anaphy-
laxis (WDEIA), unlike conventional WDEIA (CO-
WDEIA), HWP-IWA is not mediated by ω-5 gliadin.8
Currently, the skin prick test (SPT) by GP19S is
considered the most useful method in diagnosing
HWP-IWA.7 It would be advantageous to develop a
quantitative, high-throughput method for the labora-
tory diagnosis of HWP-IWA that gives consistent re-
sults across different institutions. For this purpose,
we evaluated the utility of GP19S-specific IgE anti-
body detection by enzyme-linked immunosorbent as-
say (ELISA) for the diagnosis of HWP-IWA using
sera from healthy individuals and from patients with
CO-WDEIA or HWP-IWA. Five institutions were in-
volved in this study to assess the reliability of this
method.
METHODS
SUBJECTS
The HWP-IWA group consisted of 24 patients diag-
nosed with immediate-type wheat allergy induced by
GP19S according to the diagnostic criteria by Special
Committee for the Safety of Protein Hydrolysates in
Cosmetics; CO-WDEIA group consisted of 10 pa-
tients with conventional WDEIA; and the healthy con-
trol group consisted of 10 individuals without wheat
allergy (Table 1, 2). HWP-IWA patient 1 to 14, CO-
WDEIA patient and healthy control 1 to 5 were used
for utility evaluation of ELISA-based GP19S-specific
IgE assay. HWP-IWA patient 15 to 24, CO-WDEIA pa-
tient and healthy control 6 to 10 were used for valida-
tion this method. Patients 1 to 14 in the HWP-IWA
group were classified into the following four grades
of severity based on symptoms after wheat ingestion:
grade 1, eyelid swelling, symptoms limited to the face
and nasal mucosa; grade 2, generalized urticaria in
addition to grade 1 symptoms; grade 3, systemic
symptoms (e.g. dyspnea, diarrhea) in addition to der-
mal swelling; and grade 4, anaphylactic shock. The
presence of specific serum IgE was determined using
ImmunoCAP (Thermo Fisher Scientific, Phadia AB,
Uppsala, Sweden). Sensitivity to GP19S was evalu-
ated using SPT.
ELISA-BASED GP19S-SPECIFIC IgE ASSAY
GP19S (Katayama Chemical Industries) at 1 mgml
dissolved in phosphate-buffered saline (PBS) was
centrifuged and the supernatant was recovered
(GP19S solution). Next, 100 μl of GP19S solution was
added to each well of a Nunc MaxiSorp flat bottom
96-well plate (Thermo Fisher Scientific, Waltham,
MA, USA), and the plate was sealed and left over-
night at 4°C. The plate was blocked with 1% skim
milkPBS with 0.1% Tween 20 (PBS-T) for 1 hour at
room temperature, after which 100 μl patients’ sera
diluted to 20% in 1% skim milkPBS-T were added to
the wells, followed by a further incubation for 1 hour
at room temperature. The plate was then washed
with 1% skim milkPBS-T. A total of 100 μl of 0.1 μg
ml anti-human IgE-HRP conjugate (KPL, Gaithers-
burg, MD, USA) in 1% skim milkPBS-T was added
to the wells, and the plate was incubated for 1 hour at
room temperature. The plate was washed, and the
colorimetric reaction was developed by adding 1-Step
Ultra TMB-ELISA (Thermo Fisher Scientific) and in-
cubated for 15 min at room temperature. The reac-
tion was stopped by adding 2 M H2SO4. Absorbance
was measured by multi-plate optic densitometories,
VersaMax (Molecular Devices, Sunnyvale, CA, USA),
with a wavelength of 450 nm.
CONVERSION OF ABSORBANCE INTO “UNIT”
VALUES
Serum taken from HWP-IWA patient 5 was chosen as
the standard. Serial dilution was performed using 1%
skim milkPBS-T, starting at 40 times dilution, with
subsequent doubling of the dilution factor up to 5120
times dilution. The GP19S-specific IgE ELISA was
performed as described above. To create a curve for
the conversion of absorbance values to “unit” values,
the absorbance of the 40 times-diluted serum was de-
fined as that corresponding to 100.0 units, with the
absorbance of the 80 times-diluted serum as 50.0
units, and that of the 640 times-diluted serum as 6.3
units, and so forth, such that the absorbance at each
dilution factor corresponds to a “unit” value. For each
Test Method for HWP-IWA
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Table　1　Clinical characteristics of the patients with HWP-IWA
ID Age Sex Past allergic history Severity
CAP-FEIA GP19SSkin prick test
wheat-sIgE gluten-sIgE ω-5 gliadin-sIgE Threshold for 
positive  prick 
reaction (%)(UA/mL) (Class) (UA/mL) (Class) (UA/mL) (Class)
HWP-IWA 1 47 F Pollinosis 4 4.52 3 7.16 3 0.34> 0 0.001
HWP-IWA 2 38 F Pollinosis, Graves disease 4 4.1 3 4.71 3 0.34> 0 0.0001
HWP-IWA 3 43 F Non 4 2.21 2 1.94 2 0.34> 0 0.01
HWP-IWA 4 18 F Atopic dermatitis, Asthma, 
Pollinosis
4 2.28 2 5.37 3 0.71 2 0.01
HWP-IWA 5 45 F Atopic dermatitis (Child-
hood), Rhinitis, Pollinosis
4 25.1 4 57.3 5 0.68 1 0.001
HWP-IWA 6 61 F Pollinosis 3 0.72 2 0.98 2 0.34> 0 0.001
HWP-IWA 7 62 F Non 4 4.44 3 6.41 3 0.34> 0 0.001
HWP-IWA 8 33 F Pollinosis 3 <0.35 0 <0.35 0 0.34> 0 0.01
HWP-IWA 9 44 F Non 3 0.35 1 0.73 2 0.34> 0 0.001
HWP-IWA 10 49 F Rhinitis 2 1.08 2 1.53 2 0.34> 0 0.001
HWP-IWA 11 43 F Non 3 3.6 3 7.89 3 1.29 2 0.001
HWP-IWA 12 37 F Non 2 0.67 1 1.41 2 0.34> 0 0.001
HWP-IWA 13 63 F Contact dermatitis 1 <0.35 0 0.56 1 0.34> 0 0.01
HWP-IWA 14 30 F Rhinitis, Pollinosis,
Metal allergy
1 0.45 1 0.75 2 0.34> 0 0.10
sIgE, specifi c IgE.
Severity: 1: eyelid swelling, symptoms limited to face and nasal mucosa; 2: generalized urticaria besides Stage 1 symptoms; 3: general 
symptoms in addition to dermal disorders (diarrhea, dyspnea, etc.); 4: anaphylactic shock.
GP19S Skin prick test : GP19S was diluted to 100 μg/ml in sterile physiologic saline (PS) and then made into solutions at concentration 
from 0.00001% to 0.1%. Reactions were read at 15 min, a wheal at least half the size of that caused by histamine dihydrochloride (10 mg/
ml) or 3 mm was considered a positive reaction.
serum, a “unit” value was obtained from the meas-
ured absorbance with 5 times-diluted serum samples
according to this curve.
CORRELATION BETWEEN LABORATORY VAL-
UES AND CLINICAL SEVERITY
Pearson’s correlation coefficient (Pearson’s product-
moment correlation coefficient, represented by the
letter r), between grades of severity and the following
test values were calculated: wheat-specific IgE (UA
mL), gluten-specific IgE (UAmL), ω-5 gliadin-
specific IgE (UAmL), GP19S SPT positive concen-
tration (%), and GP19S-specific IgE (unit).
VALIDATION STUDY OF THE ELISA-BASED
GP19S-SPECIFIC IgE ASSAY AT FIVE INSTITU-
TIONS
In order to validate and determine the inter-
laboratory reproducibility of the ELISA-based GP19S-
specific IgE Assay, the method was performed at five
institutions affiliated with members of the Special
Committee for the Safety of Protein Hydrolysates in
Cosmetics. A manual was complied and distributed
prior to the study to ensure common understanding
of the technique and to allow discussion of uncertain-
ties. All participating institutions used the same re-
agents and consumables that were prepared by mem-
bers of Fujita Health University School of Medicine.
The microplate reader for absorbance detection and
other laboratory equipment were prepared by each
institution. ELISA was performed using sera from 10
HWP-IWA and five CO-WDEIA patients, as well as
five healthy subjects. Each sample was tested in du-
plicates to obtain absorbance and unit values. The ab-
sorbance and unit values obtained by all five institu-
tions were examined to determine the validity of the
test conditions. The standard deviation (SD) of absor-
bance and unit values was calculated to assess inter-
laboratory reproducibility.
ETHICAL CONSIDERATION
This study was approved by the Ethics Committee of
Fujita Health University (No. 11-210). Venous blood
samples were collected with patients’ informed con-
sent.
RESULTS
ELISA-BASED GP19S-SPECIFIC IgE ASSAY
The range of measured absorbance was 0.01-0.09 op-
tic density (OD) (mean, 0.04 OD) for the healthy con-
trol group (n = 5), 0.00-0.11 OD (mean, 0.05 OD) for
the CO-WDEIA group (n = 5), and 0.21-3.92 OD
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Table　2　Laboratory fi ndings of the sera from patients and controls in the validation study
ID
Total IgE
CAP-FEIA
GP19S Skin prick testwheat-sIgE gluten-sIgE ω-5 gliadin-sIgE
(U/ml) (UA/mL) (Class) (UA/mL) (Class) (UA/mL) (Class)
Healthy 6 8.16 0.34> 0 0.34> 0 0.34> 0 Nagative
Healthy 7 138 0.34> 0 0.34> 0 0.34> 0 Nagative
Healthy 8 NT NT NT NT NT NT NT NT
Healthy 9 NT NT NT NT NT NT NT NT
Healthy 10 NT NT NT NT NT NT NT NT
CO-WDEIA 6 NT 0.57 1 2.65 2 0.34> 0 Nagative
CO-WDEIA 7 NT 2.37 2 1.19 2 9.73 3 Nagative
CO-WDEIA 8 148 0.46 1 2.51 2 13.3 3 Nagative
CO-WDEIA 9 NT 3.36 3 1.48 2 NT NT Nagative
CO-WDEIA 10 NT 0.55 1 3.85 3 9.39 3 Nagative
HWP-IWA 15 3650 8.91 3 NT NT NT NT Positive
HWP-IWA 16 36 0.34> 0 0.39 1 0.34> 0 Positive
HWP-IWA 17 101 0.85 2 2.91 2 0.34> 0 NT
HWP-IWA 18 285 0.77 2 1.84 2 0.34> 0 Positive
HWP-IWA 19 82 4.25 3 7.18 3 0.34> 0 Positive
HWP-IWA 20 738 13.1 3 24.3 4 0.34> 0 Positive
HWP-IWA 21 148 4.44 3 6.41 3 0.34> 0 Positive
HWP-IWA 22 442 0.54 1 1.23 2 0.34> 0 Positive
HWP-IWA 23 2343 3.55 3 4.27 3 0.34> 0 Positive
HWP-IWA 24 67 0.4 1 0.6 1 0.34> 0 Positive
NT, Not tested; sIgE, specifi c IgE.
Skin prick test: Reactions were read at 15 min, a wheal at least half the size of that caused by histamine dihydrochloride (10 mg/ml) or 3 
mm was considered a positive reaction.
(mean, 2.10 OD) for the HWP-IWA group (n = 14).
The absorbance values of the healthy and CO-
WDEIA groups were relatively low and no marked
difference was observed between the two groups. On
the other hand, a wide range of absorbance values
were observed in the HWP-IWA group, and were
markedly different from those in the healthy and CO-
WDEIA groups (Table 3).
CONVERSION OF ABSORBANCE INTO “UNIT”
VALUES
Serial dilution of the serum sample resulted in a de-
crease in the measured absorbance, producing a stan-
dard curve. After assigning arbitrary “unit” values to
the measured absorbance at each dilution factor, the
following unit values were obtained from the meas-
ured absorbance: a range of 0.2-2.1 (mean, 1.1) for
the healthy group, 0.0-2.5 (mean, 1.3) for the CO-
WDEIA group, and 5.2-115.5 (mean, 59.5) for the
HWP-IWA group (Table 3).
CORRELATION BETWEEN LABORATORY VAL-
UES AND CLINICAL SEVERITY
The correlation coefficients of clinical severity and
wheat-, gluten- and ω-5 gliadin-specific IgE antibodies
were 0.43, 0.36 and 0.24, respectively. The correlation
coefficient of clinical severity and GP19S SPT positive
concentration was -0.53, which is high enough for
quantitative diagnosis of HWP-IWA, but not high
enough to indicate a correlation with severity. The
correlation coefficient of severity and GP19S-specific
IgE was 0.76, which was higher than all other pa-
rameters (Table 4).
VALIDATION STUDY OF ELISA-BASED GP19S-
SPECIFIC IgE ASSAY AT FIVE INSTITUTIONS
The results for GP19S-specific IgE were obtained by
each institution. Notably, the absorbance and unit val-
ues were low in the healthy and CO-WDEIA groups
but high in the HWP-IWA group across all institu-
tions. All samples were tested in duplicates and simi-
lar absorbance and unit values were obtained. The re-
spective SD for absorbance and unit values were 0.02-
0.05 OD and 0.3-0.4 in the healthy group, and 0.03-
0.04 OD and 0.2-0.6 in the CO-WDEIA group. In the
HWP-IWA group, the SD ranged from 0.19-0.31 OD
and 3.8-9.6 for HWP-IWA 16-24, and it was as high as
0.93 OD and 53.3 for HWP-IWA 15. It was observed
that the SD became higher as the GP19S-specific IgE
level increased. We consider that a high inter-
laboratory reproducibility is achieved only when the
“unit” value is below 100.0 (Table 5).
Test Method for HWP-IWA
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Table　3　Results of the ELISA-based GP19S-specifi c IgE 
assay
ID Absorbance Unit
Healthy 1 0.01 0.2
Healthy 2 0.01 0.2
Healthy 3 0.05 1.2
Healthy 4 0.07 1.6
Healthy 5 0.09 2.1
CO-WDEIA 1 0.11 2.5
CO-WDEIA 2 0.06 1.4
CO-WDEIA 3 0.00 0.0
CO-WDEIA 4 0.03 0.7
CO-WDEIA 5 0.07 1.7
HWP-IWA 1 3.92 115.5
HWP-IWA 2 3.89 114.5
HWP-IWA 3 2.60 71.3
HWP-IWA 4 3.89 114.5
HWP-IWA 5 3.89 114.5
HWP-IWA 6 3.60 104.0
HWP-IWA 7 2.54 69.7
HWP-IWA 8 0.28 6.9
HWP-IWA 9 0.43 10.8
HWP-IWA 10 1.49 39.0
HWP-IWA 11 1.20 30.9
HWP-IWA 12 1.10 28.3
HWP-IWA 13 0.35 8.7
HWP-IWA 14 0.21 5.2
Absorbance,  absorbance at 450 nm.
Table　4　Correlation between clinical severity and laboratory 
fi ndings
r p
wheat-specifi c IgE (UA/mL) 0.43 0.12
gluten-specifi c IgE (UA/mL) 0.36 0.20
ω-5 gliadin-specifi c IgE (UA/mL) 0.24 0.41
GP19S SPT positive concentration (%) -0.53 0.052
GP19S-specifi c IgE (unit) 0.76 0.0015
Positive concentration,  threshold for positive prick reaction.
Correlation coefficient r were calculated by Pearson’s product-
moment correlation coefficient.
Table　5　Combined ELISA results from the fi ve institutions
ID
Absorbance Unit
Mean SD Mean SD
Healthy 6 0.08 0.05 0.8 0.4
Healthy 7 0.07 0.04 0.7 0.3
Healthy 8 0.07 0.03 0.6 0.3
Healthy 9 0.08 0.02 0.8 0.3
Healthy 10 0.08 0.05 0.8 0.3
CO-WDEIA 6 0.11 0.03 1.5 0.5
CO-WDEIA 7 0.10 0.03 1.3 0.5
CO-WDEIA 8 0.08 0.03 0.8 0.2
CO-WDEIA 9 0.08 0.03 0.9 0.2
CO-WDEIA 10 0.10 0.04 1.2 0.6
HWP-IWA 15 4.36 0.93 154.1 53.3
HWP-IWA 16 3.22 0.31 97.0 9.2
HWP-IWA 17 3.06 0.23 90.1 9.6
HWP-IWA 18 3.10 0.19 92.0 8.8
HWP-IWA 19 2.60 0.28 72.0 5.9
HWP-IWA 20 2.59 0.30 71.8 5.7
HWP-IWA 21 2.38 0.24 63.6 6.1
HWP-IWA 22 1.55 0.25 36.7 3.8
HWP-IWA 23 1.73 0.24 42.3 3.9
HWP-IWA 24 1.32 0.24 30.1 4.5
Absorbance, absorbance at 450 nm.
DISCUSSION
In Japan, approximately 4.7 million people bought
46.7 million cakes of “Cha no Shizuku” soap that con-
tained GP19S. According to an epidemiological study
released online by the Japanese Society of Allergol-
ogy on 20 November 2013, there were 2026 cases of
HWP-IWA, of which 95.9% were females mainly in
their 40s. About half of these cases experienced ana-
phylactic symptoms, of which half experienced ana-
phylactic shock. Many of these patients developed
WDEIA suddenly, manifesting as eyelid edema after
eating wheat-containing food, even though no symp-
toms appeared while using the soap.7 This phenome-
non was also noted in patients in our study (Table 1).
Unsuspectingly, patients with oral wheat allergy con-
tinued to use the offending soap, highlighting the
possibility of a large number of patients who are un-
aware of their condition.
As a result of sensitization to GP19S contained in
the soap, the produced IgE cross-reacts with orally in-
gested wheat protein.8 SPT using GP19S is consid-
ered a fast and sensitive method for the diagnosis of
HWP-IWA; the condition is ruled out if the SPT using
0.1% GP19S solution is negative. However, some pa-
tients decline SPT, which causes discomfort and can
induce a severe allergic reaction. In addition to SPT,
the Special Committee for the Safety of Protein Hy-
drolysates in Cosmetics recommends other immu-
nological methods such as dot blotting, ELISA, West-
ern blotting (patient is considered HWP-IWA-positive
if GP19S-specific IgE is detected in the blood), or ba-
sophil activation test that uses GP19S as the antigen
(a positive result suggests HWP-IWA).
Reports exist regarding the diagnosis of wheat al-
lergy using various immunological methods. Western
blotting for GP19S using serum IgE antibody has
been employed at many institutions.1,2,8 Using pa-
tients’ basophils, Hiragun et al. conducted the hista-
mine release test9 and Chinuki et al. performed the
Nakamura M et al.
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CD203c expression-based basophil activation test.10
Nakamura et al. described the EXiLE (IgE Cross
linking-induced Luciferase Expression) method,
which uses a rat mast cell line expressing human IgE
antibody receptors.11 Though useful, the abovemen-
tioned methods have drawbacks. Quantitative evalu-
ation is difficult in Western blotting. Basophil-based
tests and the EXiLE method are not widely available,
and samples cannot be preserved in the former.
Continuing investigation into HWP-IWA will be re-
quired to assess the incidence, natural clinical
course, allergenicity, treatment, and appropriate pa-
tient education. We believe that the most important
issue was the development of a quantitative, high-
throughput, GP19S-specific IgE diagnostic test that
can provide consistent results at any institution. For
these reasons, we tested an ELISA-based assay that
would satisfy these conditions.
First, we compared the results of GP19S-specific
IgE measurement by ELISA between healthy con-
trols (five subjects), CO-WDEIA (five patients) and
HWP-IWA patients (14 patients). Under the de-
scribed test conditions, the measured absorbance
was high in the HWP-IWA group but low in the
healthy and CO-WDEIA groups, suggesting that
ELISA is effective for the diagnosis of HWP-IWA (Ta-
ble 3). Using the absorbance results from one pa-
tient’s serum sample (HWP-IWA 5), “unit” values
were assigned to absorbance values in order to im-
prove inter-test and inter-laboratory reproducibility.
Using one patient’s serum as a standard is disadvan-
tageous, as the created standard cannot be repro-
duced at other institutions. Therefore, dilution series
using sera from other HWP-IWA patients were per-
formed to determine whether the resulting curves
are comparable to that of HWP-IWA 5; similar curves
were obtained in each case (data not shown). This
suggests that it is unnecessary to use the sample of
HWP-IWA 5 as the standard if the relative concentra-
tion of antibodies against GP19S to HWP-IWA 5 can
be determined.
The ELISA results differed widely among HWP-
IWA patients (1 to 14); therefore, we examined the
correlation between clinical severity and laboratory
values to analyze the nature of these differences.
GP19S-specific IgE had a higher degree of correla-
tion with severity than gluten and wheat (Table 4),
suggesting that it may be predictive of symptoms ex-
perienced by HWP-IWA patients. We believe that
such data will be useful in gauging the effect of treat-
ment and for patient education. The ELISA-based GP
19S-specific IgE assay provides quantitative results
that are meaningful in predicting disease severity.
In the validation study conducted at five different
institutions, repeat tests demonstrated reproducible
results, with the HWP-IWA group consistently show-
ing higher values. This suggests that the test condi-
tions were appropriate. However, it was noted that
one sample (HWP-IWA 15) had a high SD of 53.3,
which was different from the SD of the HWP-IWA
(<9.6), CO-WDEIA (<0.6) and healthy groups (<0.4)
(Table 5). The absorbance of HWP-IWA 15 sample
exceeded the maximum measurable limit of the mi-
croplate reader at each institution, thus causing the
large SD. To ensure inter-laboratory reproducibility,
we practically set the maximum “unit” value at 100.0.
A total of 10 healthy subjects, 10 CO-WDEIA and
24 HWP-IWA patients were examined in the present
study. The respective maximum unit values in the
healthy and CO-WDEIA groups were 2.1 and 2.5
units, while the minimum unit value in the HWP-IWA
group was 5.2 units. Therefore, taking between 2.5 to
5.2 the cut-off value, the diagnostic criterion was set
as follows: <3.0, negative; 3.0-5.0, suspected; >5.0,
positive. Results based on this criterion were consis-
tent with available SPT results. Cases (HWP-IWA 8,
16 and 24) with negative ImmunoCAP results (class 2
and above were considered positive) were positive
based on this criterion. These observations suggest
that our ELISA-based GP19S-specific IgE assay is a
sensitive diagnostic method.
Our findings suggest that the ELISA-based GP19S-
specific IgE assay is a useful quantitative and high-
throughput method for the diagnosis of HWP-IWA.
This method enables the examination and diagnosis
of cases nationwide using a laboratory-based, measur-
able criterion. Hiragun et al. studied wheat- and
gluten-specific IgE antibodies with CAP-FEIA, and
glutenin-specific IgE with histamine-release test, con-
cluding that HWP-IWA may get better over time.9 We
believe that the results of the ELISA-based GP19S-
specific IgE assay accurately reflect the clinical situ-
ation. We envisage that this method will be useful not
only for patients and doctors, but also for medical re-
searchers and cosmetics makers. Many challenges
remain regarding this disease, but we expect our test
method to advance the diagnosis of this condition.
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